Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2015
At a glance
- Drugs CNF 2024 (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Biogen
- 11 Aug 2014 According to the European Clinical Trials Database record, status changed from active, no longer recruiting to completed.
- 16 Jun 2011 Planned End Date changed from 1 Nov 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 06 Jan 2011 Planned end date changed from 1 Sep 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.